|Articles|August 24, 2022

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

New partnership will accelerate Phase III study in patients with atrial fibrillation.

physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!